Previous 10 | Next 10 |
2023-10-31 14:28:31 ET Summary Sarepta Therapeutics' stock plummets after its gene therapy drug ELEVIDYS fails to meet its primary endpoint in a confirmatory study. SRPT had previously secured accelerated approval for ELEVIDYS to treat Duchenne Muscular Dystrophy from the FDA. ...
2023-10-31 12:47:58 ET Summary EMBARK study mixed results: Elevidys missed primary endpoint but showed strong secondary outcomes, affecting FDA approval calculus for DMD. Strong financials: Q2 revenue growth and a 33.6-month cash runway diminish near-term financing risk; operation...
2023-10-31 11:52:06 ET Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark study evaluating Elevidys in treating young patients with Duchen...
2023-10-31 10:00:02 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further details see: Sarepta Therapeutics, Petmed Express among healthcare movers
2023-10-31 09:14:03 ET More on Sarepta Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst Sarepta Eyes Broadened La...
2023-10-31 08:45:00 ET U.S. stock index futures on Tuesday had given up their gains to trade near the flatline, pointing to a cautious open. In the previous session, all three major Wall Street averages posted gains of more than 1% each, rebounding from a bruising two-week sell-off...
2023-10-31 08:31:19 ET Losers: Sarepta Therapeutics ( SRPT ) -43% announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. Petmed Express PETS -26% after Q2 earning release . SELLAS Life Science...
2023-10-30 17:21:28 ET More on Sarepta Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst Sarepta Eyes...
– Results support submission of an efficacy supplement to the BLA; US FDA has indicated openness to reviewing the data for label expansion based on the totality of evidence from EMBARK – In EMBARK, participants treated with ELEVIDYS (delandistrogene moxeparvovec-rokl...
2023-10-27 17:09:46 ET Gainers: Coherus BioSciences ( CHRS ) +16% . 2U ( TWOU ) +6% . Sarepta Therapeutics ( SRPT ) +5% . Noodles & Company ( NDLS ) +4% . Intuitive Machines ( LUNR ) +4% . Losers: NKGen Biotech ( NK...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...